Seelos Therapeutics has signed an agreement with Duke University in North Carolina to conduct a pre-clinical study of SLS-004, one of its gene therapy candidates, as a treatment for Parkinson’s disease. The proof-of-concept study will seek to determine if the investigational therapy can prevent or delay Parkinson’s disease…
News
Simvastatin, a widely-used cholesterol-lowering medication, failed to slow the progression of Parkinson’s disease, according to data from a Phase 2 trial. Based on these findings, it was decided that a future Phase 3 study assessing the safety and efficacy of simvastatin in these patients would not be…
The Aligning Science Across Parkinson’s (ASAP) initiative has awarded a $7.2 million grant to a research team working to unravel the structure and biology of leucine-rich repeat kinase 2 (LRRK2), a protein linked to familial Parkinson’s disease. The three-year grant, issued by the Michael J. Fox Foundation (MJFF), was…
Reduced protein synthesis could serve as a biomarker to help diagnose Parkinson’s disease, even before motor symptoms appear, a recent study suggests. The study, “Protein synthesis is suppressed in sporadic and familial Parkinson’s disease by LRRK2,” was published in The FASEB Journal. The LRRK2 protein (leucine-rich repeat…
Fatigue increases over time in people with Parkinson’s disease and is associated with several factors, including sex, age, depression symptoms, and higher cognitive function, a study has found. The results of the longitudinal study, “Progression of fatigue in Parkinson’s disease – A nine-year follow-up,” were published…
Cognitive changes in people with Parkinson’s disease pose a substantial challenge for their care partners, new research suggests. The findings were presented at the 2020 Congress of Parkinson’s Disease and Movement Disorders (held virtually due to the COVID-19 pandemic) by researchers from the Parkinson’s Foundation, in…
A new webinar titled “Is Parkinson’s Inherited?” — led by a research vice president at the Michael J. Fox Foundation (MJFF) — focused on the genetics and heritability of Parkinson’s disease and spoke to the need for greater diversity in clinical trials. The MJFF’s latest Third Thursday Webinar,…
The United Kingdom’s Medical Research Council (MRC) and the Japan Agency for Medical Research and Development (AMED) are collaborating to support eight new regenerative medicine projects seeking to develop therapies for disorders such as Parkinson’s disease (PD). The landmark £7 million (about $9 million)…
The Parkinson’s Foundation is launching a large paper-based survey to identify gaps in existing research in traditionally underserved people with Parkinson’s disease by gathering patient-reported information about treatment and care, access, unmet needs, and outcomes. The survey was developed by the foundation, together with researchers at the…
The first participants have been dosed in the initial part of a Phase 1 clinical trial evaluating the investigational compound CST-2032 as a treatment for neurodegenerative disease, according to the therapy’s developers, CuraSen Therapeutics. The trial will enroll up to 70 healthy volunteers and patients with a variety…
Recent Posts
- Energy shortage in cells may drive toxic dopamine buildup in Parkinson’s
- Addressing a misconception that levodopa loses effectiveness over time
- New Silvi Foundation funds research into Parkinson’s and related diseases
- New national strategy urges patient-centered Parkinson’s care in US
- When love can’t put things back on track, it finds a new way to keep going